Company intelligence / Profile preview

Curadh MTR

Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Curadh MTR is advancing preclinical radiopharmaceutical oncology programs targeting solid tumors, based on proprietary molecularly targeted radiation platforms and strategic isotope supply agreements; clinical studies are anticipated in 2025-2026.[1][3]

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalMolecularly targeted radiation therapyBiologic
Industry: Biotech

Partnerships

NorthStar Medical Radioisotopes (strategic supply/clinical collaboration for actinium-225 radiopharmaceuticals)[2][8]Alpha Fusion (joint venture for astatine-211 based radiopharmaceutical development)[4][7][9]

Beyond the preview

Go deeper on Curadh MTR.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curadh MTR.

Explore the full profile